NYSE:TEVA Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Teva Pharmaceutical Industries Limited Please log in to your account or sign up in order to add this asset to your watchlist. $10.76 +0.05 (+0.47%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$10.61▼$10.8050-Day Range$8.32▼$11.3752-Week Range$6.78▼$11.44Volume7.04 million shsAverage Volume10.28 million shsMarket Capitalization$11.95 billionP/E RatioN/ADividend YieldN/APrice Target$10.67 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Teva Pharmaceutical Industries MarketRank™ ForecastAnalyst RatingHold2.00 Rating ScoreUpside/Downside0.9% Downside$10.67 Price TargetShort InterestHealthy2.25% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.04Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth-0.83%From $2.40 to $2.38 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.35 out of 5 starsMedical Sector957th out of 1,029 stocksPharmaceutical Preparations Industry463rd out of 501 stocks 1.0 Analyst's Opinion Consensus RatingTeva Pharmaceutical Industries has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 3 buy ratings, 3 hold ratings, and 3 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $10.67, Teva Pharmaceutical Industries has a forecasted downside of 0.9% from its current price of $10.76.Amount of Analyst CoverageTeva Pharmaceutical Industries has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.25% of the outstanding shares of Teva Pharmaceutical Industries have been sold short.Short Interest Ratio / Days to CoverTeva Pharmaceutical Industries has a short interest ratio ("days to cover") of 2.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Teva Pharmaceutical Industries has recently decreased by 20.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldTeva Pharmaceutical Industries does not currently pay a dividend.Dividend GrowthTeva Pharmaceutical Industries does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for TEVA. Previous Next 3.4 News and Social Media Coverage News SentimentTeva Pharmaceutical Industries has a news sentiment score of 1.04. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Teva Pharmaceutical Industries this week, compared to 5 articles on an average week.Search Interest37 people have searched for TEVA on MarketBeat in the last 30 days. This is an increase of 106% compared to the previous 30 days.MarketBeat Follows8 people have added Teva Pharmaceutical Industries to their MarketBeat watchlist in the last 30 days. This is an increase of 33% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Teva Pharmaceutical Industries insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.82% of the stock of Teva Pharmaceutical Industries is held by insiders.Percentage Held by Institutions50.39% of the stock of Teva Pharmaceutical Industries is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Teva Pharmaceutical Industries are expected to decrease by -0.83% in the coming year, from $2.40 to $2.38 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Teva Pharmaceutical Industries is -9.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Teva Pharmaceutical Industries is -9.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioTeva Pharmaceutical Industries has a P/B Ratio of 1.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Teva Pharmaceutical Industries (NYSE:TEVA) StockTeva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.Read More Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TEVA Stock News HeadlinesJanuary 30, 2023 | benzinga.comGlobal Pharmaceutical Drug Delivery Market worth $2,206.5 billion by 2026 - Exclusive Report by MarketsandMarkets™January 30, 2023 | marketwatch.comSterile Dry Powder Active Pharmaceutical Ingredient (API) Market Size [2023-2028] | Industry Share, Growth Factor, Revenue And Trends Outlook ReportFebruary 3, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 27, 2023 | finance.yahoo.comIs Teva Pharmaceutical Industries (TEVA) a Great Value Stock Right Now?January 26, 2023 | marketwatch.comIntrauterine Contraceptive Devices (IUCD) Market Register to Growth by 2023-2027 | Global Revenue and Key Dynamics with Industry SegmentsJanuary 25, 2023 | benzinga.com$31+ Billion Worldwide Contraceptives Industry to 2031 - Rising Frequency of STIs or Diseases is Driving DemandJanuary 25, 2023 | finance.yahoo.comBiotech Stock Roundup: BLUE Down on Share Issuance, CPRX Falls on Generic Filing & MoreJanuary 25, 2023 | marketwatch.comRaloxifene Hydrochloride Market Report 2023, Size, Share, Industry Growth, Trends, Major Key Players & Forecast Till 2028February 3, 2023 | Wall Street Watch Dogs (Ad)A gold storm is coming…“We are in the early stages of a mania – the calm before the storm.”...January 24, 2023 | americanbankingnews.comTeva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $10.50 Consensus Price Target from AnalystsJanuary 23, 2023 | finance.yahoo.comNo. 1 IBD 50 Stock Catalyst Tanks As Teva Looks To Knock Off Its Only ProductJanuary 23, 2023 | finance.yahoo.comCatalyst Pharma Shares Take A Hit As Teva Files For Generic Version Of Its Lead ProductJanuary 23, 2023 | marketwatch.comOTC Pharmaceutical Market Future Trends Demand 2023, and Forecast to 2028January 23, 2023 | msn.comCatalyst stock slumps ~20% as Teva seeks FDA approval of generic FirdapseJanuary 20, 2023 | marketwatch.comPharma and OTC Market 2023 : Future Developments, Key Vendors, Regional Analysis and Industry Scope by 2028January 19, 2023 | marketwatch.comChronic Kidney Disease Market 2023 : Key Product Segments, Application Analysis, and Industry Growth Forecast by 2028January 19, 2023 | marketwatch.comSleep Medicine Market Statistics 2023 : Industry Demand, Prominent Players Strategies, Size, SWOT Analysis and Forecast 2029January 18, 2023 | seekingalpha.comTeva Pharmaceutical: Stuck In A Cycle Of Hope And DisappointmentJanuary 18, 2023 | marketwatch.comPharmerging Market 2023 Industry Outlook, Current Status, Supply-Demand, Growth Opportunities and Top Players Analysis 2028January 18, 2023 | marketwatch.comTreat Oncology Drug Market 2023 : Detailed Analysis of Industry, Potential Growth, Attractive Valuation and Growth Forecast Up to 2029January 18, 2023 | marketwatch.comDepression Treatment Therapy Market 2023 Comprehensive Analysis of the Leading Players - Pfizer, Teva Pharmaceutical, Johnson and Johnson, MerckJanuary 17, 2023 | marketwatch.comParenteral Nutrition Market Size with Global Industry Analysis, Revenue, Future Growth, Business Prospects and Forecast 2023 to 2028January 11, 2023 | seekingalpha.comTeva Pharmaceutical Industries Ltd. (TEVA) Presents at 41st Annual J.P. Morgan Healthcare Conference (Transcript)January 11, 2023 | marketwatch.comLarge Volume Parenteral (LVP) Market Share From 2023 To 2028 And Unlimited Opportunities for New Companies and Latest DevelopmentsJanuary 5, 2023 | benzinga.comJazz Pharmaceuticals Files Patent Infringement Against Generic Drugmakers In New Jersey's District CourtJanuary 4, 2023 | benzinga.comActive Pharmaceutical Ingredient Global Market Report 2023: Featuring Teva Pharmaceutical, Bristol-Myers Squibb, MerckJanuary 4, 2023 | marketwatch.comBreast Cancer Therapeutics Market Research Reports, Industry Size, Growth Opportunity, Regional Analysis 2022-2031See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive TEVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter. Email Address TEVA Company Calendar Last Earnings10/27/2021Today2/03/2023Next Earnings (Confirmed)2/08/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:TEVA CUSIPN/A CIK818686 Webwww.tevapharm.com Phone(723) 914-8213Fax972-3923-4050Employees37,537Year FoundedN/APrice Target and Rating Average Stock Price Forecast$10.67 High Stock Price Forecast$13.00 Low Stock Price Forecast$7.00 Forecasted Upside/Downside-0.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E Ratio4.48 P/E GrowthN/ANet Income$417 million Net Margins-8.52% Pretax Margin-14.14% Return on Equity26.97% Return on Assets5.96% Debt Debt-to-Equity Ratio1.94 Current Ratio0.99 Quick Ratio0.66 Sales & Book Value Annual Sales$15.88 billion Price / Sales0.75 Cash Flow$3.74 per share Price / Cash Flow2.88 Book Value$10.19 per share Price / Book1.06Miscellaneous Outstanding Shares1,110,560,000Free Float1,101,458,000Market Cap$11.95 billion OptionableOptionable Beta1.22 Key ExecutivesRichard FrancisPresident, Chief Executive Officer & DirectorEric DrapéExecutive Vice President-Global OperationsEli KalifChief Financial Officer & Executive Vice PresidentEric A. HughesChief Medical Officer, Executive VP-Global R&DKathleen VeitSenior VP-Global Compliance & Ethics OfficerKey CompetitorsUnited TherapeuticsNASDAQ:UTHRSarepta TherapeuticsNASDAQ:SRPTJazz PharmaceuticalsNASDAQ:JAZZCatalentNYSE:CTLTDr. Reddy's LaboratoriesNYSE:RDYView All CompetitorsInsiders & InstitutionsPrivate Management Group Inc.Sold 821,603 shares on 2/3/2023Ownership: 0.117%Monaco Asset Management SAMSold 59,000 shares on 2/3/2023Ownership: 0.007%U.S. Capital Wealth Advisors LLCBought 5,876 shares on 2/3/2023Ownership: 0.001%Spire Wealth ManagementSold 2,058 shares on 2/3/2023Ownership: 0.000%X Square Capital LLCSold 1,500 shares on 2/2/2023Ownership: 0.023%View All Insider TransactionsView All Institutional Transactions TEVA Stock - Frequently Asked Questions Should I buy or sell Teva Pharmaceutical Industries stock right now? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares. View TEVA analyst ratings or view top-rated stocks. What is Teva Pharmaceutical Industries' stock price forecast for 2023? 9 Wall Street analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next year. This suggests that the stock has a possible downside of 0.6%. View analysts price targets for TEVA or view top-rated stocks among Wall Street analysts. How have TEVA shares performed in 2023? Teva Pharmaceutical Industries' stock was trading at $9.12 at the beginning of the year. Since then, TEVA shares have increased by 17.7% and is now trading at $10.73. View the best growth stocks for 2023 here. Are investors shorting Teva Pharmaceutical Industries? Teva Pharmaceutical Industries saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 25,020,000 shares, a decrease of 20.5% from the December 31st total of 31,470,000 shares. Based on an average trading volume of 9,750,000 shares, the days-to-cover ratio is currently 2.6 days. View Teva Pharmaceutical Industries' Short Interest. When is Teva Pharmaceutical Industries' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023. View our TEVA earnings forecast. How can I listen to Teva Pharmaceutical Industries' earnings call? Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link. How were Teva Pharmaceutical Industries' earnings last quarter? Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its earnings results on Wednesday, October, 27th. The company reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.65 by $0.06. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $4.05 billion. Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 26.97%. Teva Pharmaceutical Industries's revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.56 earnings per share. What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings? Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of $2.40-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion. What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO? 158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees. What other stocks do shareholders of Teva Pharmaceutical Industries own? Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO). What is Teva Pharmaceutical Industries' stock symbol? Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA." Who are Teva Pharmaceutical Industries' major shareholders? Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (1.94%), Harel Insurance Investments & Financial Services Ltd. (1.36%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), AustralianSuper Pty Ltd (0.22%), Simplex Trading LLC (0.00%) and Private Management Group Inc. (0.12%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs. View institutional ownership trends. How do I buy shares of Teva Pharmaceutical Industries? Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Teva Pharmaceutical Industries' stock price today? One share of TEVA stock can currently be purchased for approximately $10.73. How much money does Teva Pharmaceutical Industries make? Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $11.92 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis. How many employees does Teva Pharmaceutical Industries have? The company employs 37,537 workers across the globe. How can I contact Teva Pharmaceutical Industries? Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050. This page (NYSE:TEVA) was last updated on 2/3/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.